Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ypsomed Holding AGXSWX:YPSN -0.63%91 Debt-to-EBITDA is 0.93 as of Mar. 2026, which is 32% below its 10-year median of 1.36. GuruFocus rates XSWX:YPSN with a GF Score™ of 91/100 and a GF Value™ of CHF396.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Ypsomed Holding AG ranks better than 64.03% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ypsomed Holding AG's Debt-to-EBITDA or its related term are showing as below:
XSWX:YPSN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09 Med: 1.36 Max: 3.37
Current: 0.8
During the past 13 years, the highest Debt-to-EBITDA Ratio of Ypsomed Holding AG was 3.37. The lowest was 0.09. And the median was 1.36.
XSWX:YPSN's Debt-to-EBITDA is ranked better than 64.03% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs XSWX:YPSN: 0.80
Ypsomed Holding AG (XSWX:YPSN) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ypsomed Holding AG Debt-to-EBITDA Related Terms
Ypsomed Holding AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ypsomed Holding AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:YPSN vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Ypsomed Holding AG (XSWX:YPSN) has a Debt-to-EBITDA of 0.93 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ypsomed Holding AG. This is 32% below median its historical median of 1.36. Over the past decade, Ypsomed Holding AG's Debt-to-EBITDA has ranged from 0.09 to 3.37. According to the industry distribution chart, Ypsomed Holding AG ranks #168 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 36%.
Is Ypsomed Holding AG's Debt-to-EBITDA too high?
Ypsomed Holding AG's current Debt-to-EBITDA of 0.93 is 32% below median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 3.37. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Ypsomed Holding AG's value of 0.93 is 40.8% below this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #168 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Ypsomed Holding AG has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #168 out of 467 companies for Debt-to-EBITDA. This puts Ypsomed Holding AG in the upper half of its industry. The industry median Debt-to-EBITDA is 1.57. Ypsomed Holding AG's value of 0.93 is 40.8% below this benchmark. Historically, Ypsomed Holding AG's own Debt-to-EBITDA has ranged from 0.09 to 3.37 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 1.57, Ypsomed Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current Debt-to-EBITDA of 0.93 is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ypsomed Holding AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current Debt-to-EBITDA is 0.93, which is 32% below median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF396.28, compared to a current price of CHF381.20 — trading 3.8% below its estimated fair value. The current Debt-to-EBITDA is 0.93, which is 32% below median its 10-year median of 1.36 and 40.8% below the Medical Devices & Instruments industry median of 1.57. Ypsomed Holding AG's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current Debt-to-EBITDA is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF381.20 is trading 3.8% below its estimated GF Value™ of CHF396.28.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for XSWX:YPSN:
Debt-to-EBITDA: 0.93 (32% below median its 10-year median of 1.36)
GF Value™: CHF396.28 vs. price of CHF381.20 (3.8% below fair value)
Industry Position: 40.8% below the Medical Devices & Instruments median (#168 of 467)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
91GF Score
Get the complete analysis for XSWX:YPSN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
